With more than 60 novel drug and biologic candidates already under review, the potential class of 2021 has bursts of activity in therapy areas that have been quiet in recent years – notably dermatology and liver and kidney disease – alongside a full pipeline in recent stalwarts like oncology and neurology.
What Pandemic Effect? US FDA’s 2021 Approval Class Is Off To Strong Start With 60+ Novel Candidates
Dermatology, chronic kidney disease and liver disease therapies stand out in a crowd of user fee goals that is actually bigger than at the same point in 2020.
